Breast Cancer Clinical Trial
Official title:
A Phase II Randomized Study of Pegylated Liposomal Doxorubicin, Cyclophosphamide Versus Epirubicin-Cyclophosphamide as Adjuvant Chemotherapy in Her2-negative Stage I and II Breast Cancer Patients
NCT number | NCT01210768 |
Study type | Interventional |
Source | TTY Biopharm |
Contact | |
Status | Recruiting |
Phase | Phase 2 |
Start date | June 2010 |
Completion date | August 2018 |
Primary objective:
- To evaluate the disease-free survival (DFS) in the two randomized arms after therapy
with LC vs. EC in chemo-naive Her2-patients with stage I or II breast cancer
Secondary objectives:
- To assess the overall survival (OS)
- To establish the safety profile by assessing the toxicities and tolerability
- To assess the quality of life (QoL)
- To evaluate survival correlation with biomarkers expression.
n/a